These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 26924198)

  • 21. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Methotrexate].
    Rau R
    Z Rheumatol; 2016 Aug; 75(6):599-603. PubMed ID: 27365027
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
    Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
    Cleland LG; Caughey GE; James MJ; Proudman SM
    J Rheumatol; 2006 Oct; 33(10):1973-9. PubMed ID: 16881100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
    J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.
    Peters MJ; Symmons DP; McCarey D; Dijkmans BA; Nicola P; Kvien TK; McInnes IB; Haentzschel H; Gonzalez-Gay MA; Provan S; Semb A; Sidiropoulos P; Kitas G; Smulders YM; Soubrier M; Szekanecz Z; Sattar N; Nurmohamed MT
    Ann Rheum Dis; 2010 Feb; 69(2):325-31. PubMed ID: 19773290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recommendations for treatment with nonsteroidal anti-inflammatory drugs].
    Bolten WW
    MMW Fortschr Med; 2005 Aug; 147(31-32):24-7. PubMed ID: 16128192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimisation of antirheumatic drug treatment in pregnancy.
    Ostesen M
    Clin Pharmacokinet; 1994 Dec; 27(6):486-503. PubMed ID: 7882637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.
    Mason JC; Libby P
    Eur Heart J; 2015 Feb; 36(8):482-9c. PubMed ID: 25433021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocorticoid safety for treating rheumatoid arthritis.
    Rasch LA; Bultink IE; van Tuyl LH; Lems WF
    Expert Opin Drug Saf; 2015 Jun; 14(6):839-44. PubMed ID: 25802019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rheumatic diseases during pregnancy].
    Fischer-Betz R
    Internist (Berl); 2012 Sep; 53(9):1047-53. PubMed ID: 22695896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dosage and toxicity of antirheumatic drugs in renal insufficiency].
    Weiner SM; Bergner R
    Z Rheumatol; 2015 May; 74(4):300-9. PubMed ID: 25962451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safe use of antirheumatic agents in patients with comorbidities.
    Makol A; Wright K; Matteson EL
    Rheum Dis Clin North Am; 2012 Nov; 38(4):771-93. PubMed ID: 23137582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.
    Visser K; Katchamart W; Loza E; Martinez-Lopez JA; Salliot C; Trudeau J; Bombardier C; Carmona L; van der Heijde D; Bijlsma JW; Boumpas DT; Canhao H; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Murphy G; Østergaard M; Pereira IA; Ramos-Remus C; Valentini G; Zochling J; Dougados M
    Ann Rheum Dis; 2009 Jul; 68(7):1086-93. PubMed ID: 19033291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.
    Van Herwaarden N; Van Den Bemt BJF; Wientjes MHM; Kramers C; Den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):843-857. PubMed ID: 28686523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug-drug interactions in antirheumatic treatment].
    Krüger K
    Z Rheumatol; 2012 Apr; 71(3):209-15; quiz 216. PubMed ID: 22527215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.